HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study

Table 2 Archived antiretroviral drug resistance mutations among study participants

Subject no.	Major NRTI resistance mutations		Major NNRTI resistance mutations	Major PI resistance mutations
Subject no.	Non-TAMs	TAMs	Major NNRTI resistance mutations	Major PI resistance mutations
1	184V	67N, 70R, 219Q	103N	ND
2	184V, 74V	67N, 70R, 219Q	181C, 190A	ND
3	184V	41L, 210W, 215Y	ND	ND
4	184V	70R	ND	ND
5	184V, 74I	41L, 67N, 70R, 215F, 219Q	103N	84V, 90M
6	184V	41L, 67N, 70R, 215Y, 219Q	103N, 181C, 190S	30N, 88D
7	184V	41L, 215Y	103N	54V, 82A
8	184V	41L, 215Y	98G^a	46L
9	184I, 70E	ND	ND	ND
10	ND	ND	ND	ND

Reference: Stanford HIV Drug Resistance Database. Major HIV-1 Drug Resistance Mutations, Updated summary March 9, 2015. http://hivdb.stanford.edu
NRTI nucleoside analogue reverse transcriptase inhibitor, TAMs thymidine analogue mutations, NNRTI nonnucleoside analogue reverse transcriptase inhibitor, PI protease inhibitor, ND none detected
^aAlthough not listed as major NNRTI mutation, 98G confers resistance to nevirapine

ISSN: 1742-6405